Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.
Bolt Biotherapeutics, a US-based oncology therapy developer backed by property developer Nan Fung and pharmaceutical firms Pfizer and Novo, has filed to raise up to $100m in its initial public offering.
Founded in 2015 as a Stanford University spinout, Bolt is developing antibody drug conjugates to treat cancer and will channel part of the IPO proceeds into advancing its lead product candidate, BDC-1001, through a phase 1/2 clinical trial for cancers expressing the HER2 protein.
The company aims to…
